Literature DB >> 25186792

Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism.

Silke Appel-Cresswell1, Ali H Rajput, Vesna Sossi, Christina Thompson, Vanessa Silva, Jessamyn McKenzie, Katherine Dinelle, Siobhan E McCormick, Carles Vilariño-Güell, A Jon Stoessl, Dennis W Dickson, Chris A Robinson, Matthew J Farrer, Alex Rajput.   

Abstract

BACKGROUND: Families of Dutch-German-Russian Mennonite descent with multi-incident parkinsonism have been identified as harboring a pathogenic DNAJC13 p.N855S mutation and are awaiting clinical and pathophysiological characterization.
METHODS: Family members were examined clinically longitudinally, and 5 underwent dopaminergic PET imaging. Four family members came to autopsy.
RESULTS: Of the 16 symptomatic DNAJC13 mutation carriers, 12 had clinically definite, 3 probable, and 1 possible Parkinson's disease (PD). Symptoms included bradykinesia, tremor, rigidity, and postural instability, with a mean onset of 63 years (range, 40-85) and slow progression. Eight of ten subjects who required treatment had a good levodopa response; motor complications and nonmotor symptoms were observed. Dopaminergic PET imaging revealed rostrocaudal striatal deficits typical for idiopathic PD in established disease and subtle abnormalities in incipient disease. Pathological examinations revealed Lewy body pathology.
CONCLUSION: PD associated with a DNAJC13 p.N855S mutation presents as late-onset, often slowly progressive, usually dopamine-responsive typical PD.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  DNAJC13; Lewy Body Pathology; Mennonite; Parkinson's disease (PD); Positron Emission Tomography (PET); familial PD

Mesh:

Substances:

Year:  2014        PMID: 25186792     DOI: 10.1002/mds.26019

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients.

Authors:  O Lorenzo-Betancor; K Ogaki; A I Soto-Ortolaza; C Labbe; R L Walton; A J Strongosky; J A van Gerpen; R J Uitti; P J McLean; W Springer; J Siuda; G Opala; A Krygowska-Wajs; M Barcikowska; K Czyzewski; A McCarthy; T Lynch; A Puschmann; I Rektorova; Y Sanotsky; C Vilariño-Güell; M J Farrer; T J Ferman; B F Boeve; R C Petersen; J E Parisi; N R Graff-Radford; D W Dickson; Z K Wszolek; O A Ross
Journal:  Eur J Neurol       Date:  2015-09       Impact factor: 6.089

Review 2.  DnaJ/Hsp40 Family and Parkinson's Disease.

Authors:  Takafumi Hasegawa; Shun Yoshida; Naoto Sugeno; Junpei Kobayashi; Masashi Aoki
Journal:  Front Neurosci       Date:  2018-01-10       Impact factor: 4.677

Review 3.  New Genes Causing Hereditary Parkinson's Disease or Parkinsonism.

Authors:  Andreas Puschmann
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

Review 4.  Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process.

Authors:  Amin Karimi-Moghadam; Saeid Charsouei; Benjamin Bell; Mohammad Reza Jabalameli
Journal:  Cell Mol Neurobiol       Date:  2018-04-26       Impact factor: 5.046

Review 5.  Parkinson's Disease: Biomarkers, Treatment, and Risk Factors.

Authors:  Fatemeh N Emamzadeh; Andrei Surguchov
Journal:  Front Neurosci       Date:  2018-08-30       Impact factor: 4.677

Review 6.  The Role of TMEM230 Gene in Parkinson's Disease.

Authors:  Hao Deng; Kuan Fan; Joseph Jankovic
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

Review 7.  Beware of Misdelivery: Multifaceted Role of Retromer Transport in Neurodegenerative Diseases.

Authors:  Shun Yoshida; Takafumi Hasegawa
Journal:  Front Aging Neurosci       Date:  2022-05-06       Impact factor: 5.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.